Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Extension Study of Enzalutamide in Prostate Cancer
NCT01534052Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Oct 2011
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of enzalutamide in castration-resistant prostate cancer (CRPC), sponsored by Astellas Pharma. Primary endpoint: Number of Participants With Adverse Events. Started Oct 2011; status: completed.
02
Drugs
enzalutamide
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT01534052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01534052.